{"id":1111,"date":"2017-06-23T15:25:44","date_gmt":"2017-06-23T07:25:44","guid":{"rendered":"http:\/\/asiabiobank.com\/for-patients\/ibs-irritable-bowel-syndrome-alternative-treatment-fmt-therapy\/"},"modified":"2018-04-18T19:11:15","modified_gmt":"2018-04-18T11:11:15","slug":"ibs-irritable-bowel-syndrome-alternative-treatment-fmt-therapy","status":"publish","type":"page","link":"http:\/\/asiabiobank.com\/zh-hant\/for-patients\/gi-conditions\/ibs-irritable-bowel-syndrome-alternative-treatment-fmt-therapy\/","title":{"rendered":"\u80a0\u6613\u6fc0\u7efc\u5408\u5f81"},"content":{"rendered":"<h2>\u8178\u6613\u6fc0\u7d9c\u5408\u75c7 Irritable Bowel Syndrome (IBS)<\/h2>\n<p>\u8178\u6613\u6fc0\u7d9c\u5408\u75c7\u6703\u5f71\u97ff\u6d88\u5316\u7cfb\u7d71\uff0c\u4e3b\u8981\u662f\u5927\u8178\uff0c\u5c0f\u8178\u4e5f\u6709\u6a5f\u6703\u53d7\u5f71\u97ff\u3002\u4e5f\u88ab\u7a31\u70ba\u5927\u8178\u6025\u71e5\u75c7\uff0c\u7c98\u6db2\u6027\u7d50\u8178\u708e\uff0c\u75d9\u6523\u6027\u5927\u8178\u6216\u75d9\u6523\u6027\u7d50\u8178\u708e\uff0c\u4ee5\u53ca\u80c3\u7ffb\u9a30\u3002\u67d0\u4e9b\u5730\u5340\uff0c\u67091\/5\u7684\u4eba\u53e3\u53d7IBS\u7684\u5f71\u97ff\u3002\u800c\u5728\u9999\u6e2f\uff0c\u5c31\u6709\u5927\u7d0410\uff05\u7684\u4eba\u53e3\u662fIBS\u60a3\u8005.1\u3002IBS\u662f\u4e00\u7a2e\u6162\u6027\u75be\u75c5\uff0c\u8178\u80c3\u6703\u9577\u671f\u5730\u8655\u65bc\u4e0d\u7a69\u5b9a\u72c0\u614b\u800c\u5f15\u8d77\u4ee5\u4e0b\u75c7\u72c0\uff1a<\/p>\n<table style=\"height: 86px;\" width=\"508\">\n<tbody>\n<tr>\n<td width=\"284\">\u2022 \u809a\u7009<br \/>\n\u2022 \u4fbf\u79d8<br \/>\n\u2022 \u75d9\u6523\u6027\u8179\u75db<br \/>\n\u2022 \u5927\u4fbf\u5e36\u6709\u9ecf\u6db2<\/td>\n<td width=\"284\">\u2022 \u5927\u4fbf\u7570\u5e38<br \/>\n\u2022 \u809a\u8139<br \/>\n\u2022 \u75b2\u5026<br \/>\n\u2022 \u865b\u5f31<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<p>IBS\u5f71\u97ff\u5728\u5927\u8178\u4e2d\u7684\u83cc\u7fa4\u751f\u614b\uff0c\u5f15\u8d77\u8178\u80c3\u8d85\u654f\u53cd\u61c9\uff0c\u6703\u5c0e\u81f4\u8178\u9053\u8815\u52d5\u4e0d\u826f\uff08\u8907\u5408\u4f4d\u79fb\u904b\u52d5 migrating motor complex\uff09\u51fa\u73fe\u4fbf\u79d8\u60c5\u6cc1\u6216\u56e0\u8178\u9053\u901a\u900f\u6027\uff08\u6f0f\u8178 leaky gut\uff09\u800c\u5f15\u8d77\u7684\u6162\u6027\u708e\u75c7\u53ca\u75b2\u52de\u3002\u4ee4\u5916\uff0cIBS\u6709\u6a5f\u6703\u4f7f\u5c0f\u8178\u4e2d\u7684\u7d30\u83cc\u904e\u5ea6\u751f\u9577\uff08SIBO\uff09\u6216\u5c0f\u8178\u771f\u83cc\u904e\u5ea6\u751f\u9577\uff08SIFO\uff09\uff0c\u5c0e\u81f4\u56b4\u91cd\u7684\u809a\u8139\u548c\u5927\u4fbf\u7570\u5e38\u7684\u75c7\u72c0\u3002<\/p>\n<h4><strong>\u5982\u4f55\u8a3a\u65b7\uff1f<\/strong><\/h4>\n<p>\u66ab\u6642\u4e26\u6c92\u6709\u7279\u5b9a\u7684\u6e2c\u8a66\u4f86\u8a3a\u65b7IBS\u3002\u5982\u679c\u51fa\u73fe\u4ee5\u4e0a\u7684\u75c7\u72c0\uff0c\u60a3\u8005\u9700\u8981\u4f5c\u9032\u4e00\u6b65\u9a57\u67e5\u78ba\u8a3a\u3002\u9a57\u67e5\u4e4b\u5f8c\u767c\u73fe\u4e0d\u662f\u7531\u5176\u4ed6\u7684\u8178\u80c3\u75be\u75c5\uff0c\u4f8b\u5982\u6f70\u760d\u6027\u5927\u8178\u708eUlcerative colitis\u6216 \u514b\u7f85\u6069\u75c7 Crohn\u2019s disease\u5f15\u8d77\u7684\u8178\u80c3\u4e0d\u9069\uff0c\u91ab\u751f\u4fbf\u53ef\u80fd\u5c07\u60a8\u7684\u75c5\u60c5\u78ba\u8a3a\u70baIBS\u3002\u70ba\u4e86\u66f4\u660e\u78ba\u5730\u8a3a\u65b7\uff0c\u91ab\u751f\u6703\u6aa2\u95b1\u60a3\u8005\u7684\u75c5\u6b77\u4ee5\u53ca\u904e\u5f80\u7684\u6aa2\u5831\u544a\uff0c\u4e26\u70ba\u60a3\u8005\u505a\u8eab\u9ad4\u6aa2\u67e5\u3002<\/p>\n<p><strong>\u570b\u969b\u6027IBS\u8a3a\u65b7\u689d\u4ef6\uff1a<\/strong><\/p>\n<p>\u904e\u53bb3\u500b\u6708\u5167\uff0c\u5e73\u5747\u6bcf\u5468\u81f3\u5c11\u67091\u6b21\u8179\u75db\uff0c\u4ee5\u53ca \u8207\u4ee5\u4e0b\u5169\u9805\u6216\u4ee5\u4e0a\u7684\u5927\u4fbf\u60c5\u6cc1\u76f8\u95dc\uff1a<\/p>\n<ul>\n<li>\u6392\u4fbf\u4e0d\u9806\u66a2\uff0f\u809a\u7009\u4fbf\u79d8\u4ea4\u66ff\u767c\u751f\uff0f\u6392\u4fbf\u6642\u7e3d\u6709\u6392\u4e0d\u4e7e\u6de8\u7684<\/li>\n<li>\u5927\u4fbf\u7fd2\u6163\u6539\u8b8a<\/li>\n<li>\u5927\u4fbf\u5f62\u3001\u8272\u3001\u8cea\u3001\u91cf\u7684\u6539\u8b8a<\/li>\n<\/ul>\n<p>3\u500b\u6708\u5167\u51fa\u73fe\u4ee5\u4e0a\u76f8\u95dc\u7684\u5927\u4fbf\u60c5\u6cc1\uff0c\u4e14\u5728\u91ab\u751f\u78ba\u8a3a\u524d\u81f3\u5c116\u500b\u6708\u51fa\u5167\u51fa\u73fe\u75c7\u72c0\u3002<\/p>\n<p>\u5982\u679c\u60a3\u8005\u672a\u80fd\u7b26\u5408\u4ee5\u4e0a\u689d\u4ef6\uff0c\u4f46\u60a3\u8005\u53c8\u53d7\u8457\u4ee5\u4e0a\u8178\u80c3\u4e0d\u9069\u7684\u75c7\u72c0\u5f71\u97ff\uff0c\u6709\u6a5f\u6703\u662f\u60a3\u4e0a\u529f\u80fd\u6027\u8178\u80c3\u5931\u8abfFunctional GI Disorder\uff08FGID\uff09\u3002\u5982\u6b32\u4e86\u89e3\u66f4\u591a\u95dc\u65bcFGID\uff0c\u8acb\u9ede\u64ca\u9019\u88e1\u3002<\/p>\n<h4><strong>\u70ba\u4ec0\u9ebc\u9078\u64c7\u4eba\u985e\u83cc\u7fa4\u79fb\u690d\u7642\u6cd5 Human Microbiota Transplant\uff08HMT\uff09\u4f86\u8212\u7de9 \u8178\u6613\u6fc0\u7d9c\u5408\u75c7IBS\u7684\u6709\u95dc\u75c7\u72c0\uff1f<\/strong><\/h4>\n<p>\u8178\u6613\u6fc0\u7d9c\u5408\u75c7\u662f\u4e00\u7a2e\u8907\u96dc\u7684\u591a\u767c\u6027\u8178\u80c3\u75be\u75c5\uff0c\u5305\u62ec\u8178\u9053\u904e\u654f\u53cd\u61c9\uff0c\u8178-\u8166\u76f8\u4e0d\u5354\u8abf\uff0c\u8178\u80c3\u767c\u708e\u548c\u8178\u9053\u5fae\u751f\u83cc\u7fa4\u5931\u8abfdysboisis\u3002\u67d0\u4e00\u4e9bIBS\u75c7\u72c0\u8207\u8178\u9053\u5fae\u751f\u83cc\u7fa4\u6709\u95dc\uff0c HMT\u6cbb\u7642IBS\u5df2\u5728\u4e00\u4e9b\u7814\u7a76\u4e2d\u5f97\u5230\u8a8d\u8b49\u3002\u5df2\u7d93\u6709\u591a\u904e1,500\u540dIBS\u60a3\u8005\u63a5\u53d7\u4e86HMT\u6cbb\u7642\uff0c\u800c\u5728 HMT\u6cbb\u7642\u5f8c\u7372\u5f97\u6b63\u9762\u7d50\u679c\u753136\uff05 \u4e0a\u5347\u81f364\uff05\u3002\u5728\u6700\u65b0\u7684IBS\u81e8\u5e8a\u8a66\u9a57\u4e2d\uff0c\u8d85\u904e60\uff05\u7684IBS\u60a3\u8005\u63a5\u53d7\u7cde\u83cc\u79fb\u690d\u5f8c\u75c7\u72c0\u5f97\u4ee5\u8212\u7de93\u3002<\/p>\n<h4><strong>\u4ec0\u9ebc\u662f\u9999\u6e2fHMT\u8a08\u5283 ?<\/strong><\/h4>\n<p>\u4e9e\u6d32\u76ca\u83cc\u4e2d\u5fc3\u8207\u672c\u5730\u77e5\u540d\u80c3\u8178\u75c5\u5c08\u5bb6\u7dca\u5bc6\u5408\u4f5c\u3002\u6211\u5011\u7684HMT\u6cbb\u7642\u7a0b\u5e8f\u662f\u7531\u6211\u5011\u7684\u8178\u80c3\u79d1\u5c08\u5bb6\u9867\u554f\u7684\u5efa\u8b70\u53ca\u56e0\u500b\u4eba\u9700\u8981\u800c\u8a02\u7acb\u51fa\u4f86\u3002<br \/>\n\u8a72\u8a08\u5283\u662f\u901a\u904e\u6062\u5fa9\u8178\u9053\u5167\u5fae\u751f\u7269\u83cc\u7fa4\u7684\u5e73\u8861\uff0c\u4f86\u5e6b\u52a9\u60a8\u7de9\u89e3\u4e0d\u9069\u7684\u75c7\u72c0\uff0c\u7531\u6b64\u7372\u5f97\u9577\u671f\u76ca\u8655\u3002<\/p>\n<h4><strong>\u8a08\u5283\u6982\u8981:<\/strong><\/h4>\n<ul>\n<li>\u60a3\u8005\u6703\u5b89\u6392\u57282-3\u9031\u5167\u63a5\u53d7\u9023\u7e8c\u4e94\u5929HMT\u7642\u7a0b\uff0c\u6216\u662f\u5169\u6b21\u7684\u4e94\u5929HMT\u7642\u7a0b\uff08\u7e3d\u517110\u5929\uff09\u3002<\/li>\n<li>HMT\u53ef\u901a\u904e\u704c\u8178\uff0c\u53e3\u670d\u81a0\u56ca\u6216\u7d50\u8178\u93e1\uff08\u9700\u8981\u984d\u5916\u8cbb\u7528\uff09\u4e0b\u503c\u5165\u5230\u8178\u9053\u5167\u3002<\/li>\n<li>\u5728\u63a5\u53d7HMT\u6cbb\u7642\u4e4b\u524d\uff0c\u500b\u9ad4\u5c07\u7d93\u6b77\u7531\u6a19\u6e96\u7684\u8178\u9053\u6e96\u5099\u6216\u7d50\u8178\u6c34\u704c\u6d17\u7d44\u6210\u7684\u8178\u9053\u6e96\u5099\u3002<\/li>\n<\/ul>\n<h4><strong>\u75c5\u4eba\u9808\u77e5<\/strong><\/h4>\n<p>\u4eba\u985e\u83cc\u7fa4\u79fb\u690d\u7642\u6cd5\uff08HMT\uff09\u4e3b\u8981\u76ee\u7684\u662f\u91cd\u65b0\u5e73\u8861\u60a3\u8005\u8178\u9053\u4e2d\u7684\u5fae\u751f\u7269\u7fa4\uff0c\u9019\u53ef\u4ee5\u8212\u7de9\u60a3\u8005\u8178\u9053\u7684\u76f8\u95dc\u75c7\u72c0\u3002\u6f70\u760d\u6027\u7d50\u8178\u708e\u662f\u4e00\u7a2e\u91ab\u5b78\u75be\u75c5\uff0c\u6cbb\u7642\u5fc5\u9808\u8981\u5728\u91ab\u751f\u7684\u76e3\u7763\u4e0b\u9032\u884c\u3002\u5982\u6709\u4efb\u4f55\u6709\u95dc\u85e5\u7269\u4e0a\u6216\u8655\u65b9\u4e0a\u7684\u554f\u984c\u8acb\u8aee\u8a62\u4f60\u5bb6\u5ead\u91ab\u751f\u3002\u56e0\u6b64\uff0c\u60a3\u8005\u5728\u63a5\u53d7\u6cbb\u7642\u4e4b\u524d\uff0c\u5fc5\u9808\u8981\u7372\u5f97\u91ab\u751f\u7c3d\u767c\u7684\u8f49\u4ecb\u4fe1\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"text-decoration: underline;\"><strong>Scientific Article Abstract 1:<\/strong><\/span><\/p>\n<p style=\"margin-bottom: 7.5pt; text-align: justify;\"><b><span lang=\"EN-AU\">Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial<\/span><\/b><\/p>\n<p style=\"margin-bottom: 7.5pt; text-align: justify;\"><i><span lang=\"EN-AU\" style=\"font-size: 10.0pt;\">Peter Holger Johnsen, Frank Hilp\u00fcsch, Jorunn Pauline Cavanagh, Ingrid Sande Leikanger, Caroline Kolstad, Per Christian Valle, Rasmus Goll<\/span><\/i><\/p>\n<p style=\"margin-bottom: 7.5pt; text-align: justify;\"><i><span lang=\"EN-AU\" style=\"font-size: 10.0pt;\">Lancet Gastroenterol Hepatol 2017<\/span><\/i><\/p>\n<p style=\"margin-bottom: 7.5pt; text-align: justify;\"><span lang=\"EN-AU\">Between Jan 1, and Oct 30, 2015, we recruited 90 participants and randomly assigned them to active treatment (n=60) or placebo (n=30). Three participants did not undergo FMT and four were excluded after diagnosis of microscopic colitis, leaving 83 for final modified intention-to-treat analysis (55 in the active treatment group and 28 in the placebo group). <\/span><\/p>\n<p style=\"margin-bottom: 7.5pt; text-align: justify;\"><span lang=\"EN-AU\">Responders: 36 (65%) of 55 participants receiving active treatment versus 12 (43%) of 28 receiving the placebo showed response at 3 months (p=0\u00b7049). <\/span><\/p>\n<p style=\"margin-bottom: 7.5pt; text-align: justify;\"><span lang=\"EN-AU\">FMT induced significant symptom relief in patients with IBS. However, larger multicentre studies are needed to confirm the results.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"text-decoration: underline;\"><strong>Article Abstract 2:<\/strong><\/span><\/p>\n<h3><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28105618\">Efficacy analysis of fecal microbiota transplantation in the treatment of 406 cases with gastrointestinal disorders<\/a><\/h3>\n<div class=\"lang\">[Article in Chinese]<\/div>\n<div class=\"auths\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Li%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28105618\">Li N<\/a><sup>1<\/sup>, <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Tian%20H%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28105618\">Tian H<\/a>, <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Ma%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28105618\">Ma C<\/a>, <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Ding%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28105618\">Ding C<\/a>, <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Ge%20X%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28105618\">Ge X<\/a>, <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Gu%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28105618\">Gu L<\/a>, <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Zhang%20X%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28105618\">Zhang X<\/a>, <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Yang%20B%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28105618\">Yang B<\/a>, <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Hua%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28105618\">Hua Y<\/a>, <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Zhu%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28105618\">Zhu Y<\/a>, <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Zhou%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28105618\">Zhou Y<\/a>.<\/div>\n<div class=\"afflist\">\n<h3><a id=\"ui-ncbitoggler-1\" class=\"jig-ncbitoggler ui-widget ui-ncbitoggler\" title=\"Open\/close author information list\" role=\"button\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28105618#\" aria-expanded=\"false\"><span class=\"ui-ncbitoggler-master-text\">Author information<\/span><\/a><\/h3>\n<div class=\"ui-helper-reset\" aria-live=\"assertive\"><\/div>\n<\/div>\n<div class=\"abstr\">\n<h3>OBJECTIVE:<\/h3>\n<div class=\"\">\n<p>To evaluate the efficacy and safety of fecal microbiota transplantation (FMT) for gastrointestinal disorders.<\/p>\n<h4>METHODS:<\/h4>\n<p>Retrospective analysis of the clinical data of 406 patients who underwent FMT from May 2014 to April 2016 in the Intestinal Microenvironment Treatment Centre of Nanjing General Hospital was performed, including patients with constipation(276 cases), recurrent Clostridium Difficile infection (RCDI, 61 cases), ulcerative colitis(44 cases), irritable bowel syndrome (15 cases) and Crohn&#8217;s disease(10 cases). Donors were completely unrelated, 18- to 50-year-old non-pregnant healthy adult, with healthy lifestyle and habits, without taking antibiotics, probiotics and other probiotics history within 3 months. There were three routes of FMT administration: patients received 6 days of frozen FMT by nasointestinal tube placed in the proximal jejunum under gastroscope (319 cases); patients received capsules FMT per day for 6 consecutive days (46 cases) or once 600 ml of treated fecal liquid infusion into colon and terminal ileum by colonoscopy(41 cases).<\/p>\n<h4>RESULTS:<\/h4>\n<p>Clinical cure rate and improvement rate of different diseases receiving FMT were respectively as follows: RCDI was 85.2% (52\/61) and 95.1%(58\/61); constipation was 40.2%(111\/276) and 67.4%(186\/276); ulcerative colitis was 34.1%(15\/44) and 68.2% (30\/44); irritable bowel syndrome was 46.7% (7\/15) and 73.3% (11\/15) and Crohn disease was 30.0%(3\/10) and 60.0%(6\/10). RCDI had the best efficacy among these diseases(P&lt;0.01). There was no significant difference between the three routes of FMT administration(P=0.829). The clinical cure rate and improvement rate of different routes were 43.3%(138\/319) and 58.6% (187\/319) respectively in nasogastric transplantation group, 41.5%(17\/41) and 61.0%(25\/41) in colonoscopy group, 37.0%(17\/46) and 63.0% (29\/46) in the capsule transplantation group. There was no serious adverse event during the follow-up. The most common side effects were respiratory discomfort (27.3%, 87\/319) and increased venting (51.7%, 165\/319) in nasogastric transplantation group. Diarrhea was the most common complication in colonoscopy group (36.6%, 15\/41). The main symptoms were increased venting (50.0%, 23\/46) and nausea(34.8%, 16\/46) in oral capsule group. Side effect symptoms disappeared after the withdraw of nasogastric tube, or at the end of treatment, or during hospitalization for 1-3 days.<\/p>\n<h4>CONCLUSIONS:<\/h4>\n<p>FMT is effective for many gastrointestinal disorders. No significant adverse event is found, while the associated mechanism should be further explored.<\/p>\n<\/div>\n<\/div>\n<p>&nbsp;<\/p>\n<p><span style=\"text-decoration: underline;\"><strong>Article Abstract 3:<\/strong><\/span><\/p>\n<h3><a href=\"http:\/\/www.medscape.com\/viewarticle\/776501_\">Fecal Microbiota Transplantation Past, Present and Future<\/a><\/h3>\n<p>Olga C. Aroniadis; Lawrence J. Brandt<br \/>\nCurr Opin Gastroenterol. 2013;29(1):79-84.<\/p>\n<p>&#8220;Treatment of Gastrointestinal Diseases: Irritable Bowel Syndrome and Chronic Constipation<\/p>\n<p>Postinfectious IBS has been reported in up to 30% of patients with acute gastroenteritis, suggesting that the pathogenesis of IBS may be intimately linked to an altered intestinal microbiota.<sup>[<a>47\u201349<\/a>]<\/sup> The composition of the intestinal microbiota in patients with IBS has not been extensively studied, however, patients with constipation-predominant IBS have been shown to increase population of sulphate-reducing bacteria compared with healthy controls.<sup>[<a>50<\/a>]<\/sup> Probiotics can restore the intestinal microbiota in patients with IBS<sup>[<a>49<\/a>,<a>51<\/a>]<\/sup> and result in improvement of postinfectious IBS in animal models;<sup>[<a>11<\/a>]<\/sup> FMT, however, may prove more beneficial, as donated feces, in a sense, are the ultimate human probiotic.<\/p>\n<p>In a case series of 55 patients with IBS and IBD treated with FMT, cure was reported in 20 (36%), decreased symptoms in nine (16%) and no response in 26 (47%) patients.<sup>[<a class=\"tooltip_link\">6<\/a>]<\/sup> In another series, 45 patients with chronic constipation were treated with colonoscopic FMT and subsequent fecal enema infusions, 89% of whom (40 of 45 patients) reported relief in defecation, bloating and abdominal pain immediately after the procedure.<sup>[<a>52<\/a>]<\/sup> Normal defecation, without laxative use, persisted in 18 of 30 patients (60%) contacted 9\u201319 months later.<sup>[<a>52<\/a>]<\/sup><\/p>\n<p><span style=\"text-decoration: underline;\"><strong>Article Abstract 4:<\/strong><\/span><\/p>\n<h3><a href=\"https:\/\/www.healio.com\/gastroenterology\/irritable-bowel-syndrome\/news\/online\/%7Bd40fc27c-30ae-45ee-9963-15ab694f9399%7D\/fmt-improves-symptoms-qol-in-ibs-patients\">FMT improves symptoms, QOL in IBS patients<\/a><\/h3>\n<p><em>Healio, Gastroenterology Report<\/em><br \/>\nMay 8, 2017<\/p>\n<p>\u201cIt seems that FMT has a beneficial effect on symptom scores and on quality of life in IBS patients. However, this effect is also observed in the placebo group, although to a lesser extent, but this indicates that placebo controlled studies are definitely necessary in IBS patients,\u201d Savanne Holster, PhD, of the Nutrition-Gut-Brain Interactions Research Center at \u00d6rebro University in Sweden, said during her presentation.<\/p>\n<p>Holster and colleagues randomly assigned 16 patients with IBS to receive FMT via colonoscopy using either donor material or their own fecal material as placebo. The researchers assessed symptom scores and quality of life before and after the procedure.<\/p>\n<p>IBS Symptom Severity Scores in patients who received donor FMT dropped significantly at 4 and 8 weeks after treatment compared with baseline (P &lt; .01 for both), while there were no significant changes observed in the placebo group. There were also no significant differences observed in IBS-SSS between the treatment and placebo groups.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u8178\u6613\u6fc0\u7d9c\u5408\u75c7 Irritable Bowel Syndrome (IBS) \u8178\u6613\u6fc0\u7d9c\u5408\u75c7\u6703\u5f71\u97ff\u6d88\u5316\u7cfb\u7d71\uff0c\u4e3b\u8981\u662f\u5927\u8178\uff0c\u5c0f\u8178\u4e5f\u6709\u6a5f\u6703\u53d7\u5f71\u97ff\u3002\u4e5f\u88ab\u7a31\u70ba\u5927\u8178\u6025\u71e5\u75c7\uff0c\u7c98\u6db2\u6027\u7d50\u8178\u708e\uff0c\u75d9\u6523\u6027\u5927\u8178\u6216\u75d9\u6523\u6027\u7d50\u8178\u708e\uff0c\u4ee5\u53ca\u80c3\u7ffb\u9a30\u3002\u67d0\u4e9b\u5730\u5340\uff0c\u67091\/5\u7684\u4eba\u53e3\u53d7IBS\u7684\u5f71\u97ff\u3002\u800c\u5728\u9999\u6e2f\uff0c\u5c31\u6709\u5927\u7d0410\uff05\u7684\u4eba\u53e3\u662fIBS\u60a3\u8005.1\u3002IBS\u662f\u4e00\u7a2e\u6162\u6027\u75be\u75c5\uff0c\u8178\u80c3\u6703\u9577\u671f\u5730\u8655\u65bc\u4e0d\u7a69\u5b9a\u72c0\u614b\u800c\u5f15\u8d77\u4ee5\u4e0b\u75c7\u72c0\uff1a \u2022 \u809a\u7009 \u2022 \u4fbf\u79d8 \u2022 \u75d9\u6523\u6027\u8179\u75db \u2022 \u5927\u4fbf\u5e36\u6709\u9ecf\u6db2 \u2022 \u5927\u4fbf\u7570\u5e38 \u2022 \u809a\u8139 \u2022 \u75b2\u5026 \u2022 \u865b\u5f31 &nbsp; IBS\u5f71\u97ff\u5728\u5927\u8178\u4e2d\u7684\u83cc\u7fa4\u751f\u614b\uff0c\u5f15\u8d77\u8178\u80c3\u8d85\u654f\u53cd\u61c9\uff0c\u6703\u5c0e\u81f4\u8178\u9053\u8815\u52d5\u4e0d\u826f\uff08\u8907\u5408\u4f4d\u79fb\u904b\u52d5 migrating motor complex\uff09\u51fa\u73fe\u4fbf\u79d8\u60c5\u6cc1\u6216\u56e0\u8178\u9053\u901a\u900f\u6027\uff08\u6f0f\u8178 leaky gut\uff09\u800c\u5f15\u8d77\u7684\u6162\u6027\u708e\u75c7\u53ca\u75b2\u52de\u3002\u4ee4\u5916\uff0cIBS\u6709\u6a5f\u6703\u4f7f\u5c0f\u8178\u4e2d\u7684\u7d30\u83cc\u904e\u5ea6\u751f\u9577\uff08SIBO\uff09\u6216\u5c0f\u8178\u771f\u83cc\u904e\u5ea6\u751f\u9577\uff08SIFO\uff09\uff0c\u5c0e\u81f4\u56b4\u91cd\u7684\u809a\u8139\u548c\u5927\u4fbf\u7570\u5e38\u7684\u75c7\u72c0\u3002 \u5982\u4f55\u8a3a\u65b7\uff1f \u66ab\u6642\u4e26\u6c92\u6709\u7279\u5b9a\u7684\u6e2c\u8a66\u4f86\u8a3a\u65b7IBS\u3002\u5982\u679c\u51fa\u73fe\u4ee5\u4e0a\u7684\u75c7\u72c0\uff0c\u60a3\u8005\u9700\u8981\u4f5c\u9032\u4e00\u6b65\u9a57\u67e5\u78ba\u8a3a\u3002\u9a57\u67e5\u4e4b\u5f8c\u767c\u73fe\u4e0d\u662f\u7531\u5176\u4ed6\u7684\u8178\u80c3\u75be\u75c5\uff0c\u4f8b\u5982\u6f70\u760d\u6027\u5927\u8178\u708eUlcerative colitis\u6216 \u514b\u7f85\u6069\u75c7 Crohn\u2019s disease\u5f15\u8d77\u7684\u8178\u80c3\u4e0d\u9069\uff0c\u91ab\u751f\u4fbf\u53ef\u80fd\u5c07\u60a8\u7684\u75c5\u60c5\u78ba\u8a3a\u70baIBS\u3002\u70ba\u4e86\u66f4\u660e\u78ba\u5730\u8a3a\u65b7\uff0c\u91ab\u751f\u6703\u6aa2\u95b1\u60a3\u8005\u7684\u75c5\u6b77\u4ee5\u53ca\u904e\u5f80\u7684\u6aa2\u5831\u544a\uff0c\u4e26\u70ba\u60a3\u8005\u505a\u8eab\u9ad4\u6aa2\u67e5\u3002 \u570b\u969b\u6027IBS\u8a3a\u65b7\u689d\u4ef6\uff1a \u904e\u53bb3\u500b\u6708\u5167\uff0c\u5e73\u5747\u6bcf\u5468\u81f3\u5c11\u67091\u6b21\u8179\u75db\uff0c\u4ee5\u53ca \u8207\u4ee5\u4e0b\u5169\u9805\u6216\u4ee5\u4e0a\u7684\u5927\u4fbf\u60c5\u6cc1\u76f8\u95dc\uff1a \u6392\u4fbf\u4e0d\u9806\u66a2\uff0f\u809a\u7009\u4fbf\u79d8\u4ea4\u66ff\u767c\u751f\uff0f\u6392\u4fbf\u6642\u7e3d\u6709\u6392\u4e0d\u4e7e\u6de8\u7684 \u5927\u4fbf\u7fd2\u6163\u6539\u8b8a \u5927\u4fbf\u5f62\u3001\u8272\u3001\u8cea\u3001\u91cf\u7684\u6539\u8b8a 3\u500b\u6708\u5167\u51fa\u73fe\u4ee5\u4e0a\u76f8\u95dc\u7684\u5927\u4fbf\u60c5\u6cc1\uff0c\u4e14\u5728\u91ab\u751f\u78ba\u8a3a\u524d\u81f3\u5c116\u500b\u6708\u51fa\u5167\u51fa\u73fe\u75c7\u72c0\u3002 \u5982\u679c\u60a3\u8005\u672a\u80fd\u7b26\u5408\u4ee5\u4e0a\u689d\u4ef6\uff0c\u4f46\u60a3\u8005\u53c8\u53d7\u8457\u4ee5\u4e0a\u8178\u80c3\u4e0d\u9069\u7684\u75c7\u72c0\u5f71\u97ff\uff0c\u6709\u6a5f\u6703\u662f\u60a3\u4e0a\u529f\u80fd\u6027\u8178\u80c3\u5931\u8abfFunctional GI Disorder\uff08FGID\uff09\u3002\u5982\u6b32\u4e86\u89e3\u66f4\u591a\u95dc\u65bcFGID\uff0c\u8acb\u9ede\u64ca\u9019\u88e1\u3002 \u70ba\u4ec0\u9ebc\u9078\u64c7\u4eba\u985e\u83cc\u7fa4\u79fb\u690d\u7642\u6cd5 Human Microbiota Transplant\uff08HMT\uff09\u4f86\u8212\u7de9 \u8178\u6613\u6fc0\u7d9c\u5408\u75c7IBS\u7684\u6709\u95dc\u75c7\u72c0\uff1f \u8178\u6613\u6fc0\u7d9c\u5408\u75c7\u662f\u4e00\u7a2e\u8907\u96dc\u7684\u591a\u767c\u6027\u8178\u80c3\u75be\u75c5\uff0c\u5305\u62ec\u8178\u9053\u904e\u654f\u53cd\u61c9\uff0c\u8178-\u8166\u76f8\u4e0d\u5354\u8abf\uff0c\u8178\u80c3\u767c\u708e\u548c\u8178\u9053\u5fae\u751f\u83cc\u7fa4\u5931\u8abfdysboisis\u3002\u67d0\u4e00\u4e9bIBS\u75c7\u72c0\u8207\u8178\u9053\u5fae\u751f\u83cc\u7fa4\u6709\u95dc\uff0c HMT\u6cbb\u7642IBS\u5df2\u5728\u4e00\u4e9b\u7814\u7a76\u4e2d\u5f97\u5230\u8a8d\u8b49\u3002\u5df2\u7d93\u6709\u591a\u904e1,500\u540dIBS\u60a3\u8005\u63a5\u53d7\u4e86HMT\u6cbb\u7642\uff0c\u800c\u5728 HMT\u6cbb\u7642\u5f8c\u7372\u5f97\u6b63\u9762\u7d50\u679c\u753136\uff05 \u4e0a\u5347\u81f364\uff05\u3002\u5728\u6700\u65b0\u7684IBS\u81e8\u5e8a\u8a66\u9a57\u4e2d\uff0c\u8d85\u904e60\uff05\u7684IBS\u60a3\u8005\u63a5\u53d7\u7cde\u83cc\u79fb\u690d\u5f8c\u75c7\u72c0\u5f97\u4ee5\u8212\u7de93\u3002 \u4ec0\u9ebc\u662f\u9999\u6e2fHMT\u8a08\u5283 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":1544,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"acf":[],"_links":{"self":[{"href":"http:\/\/asiabiobank.com\/zh-hant\/wp-json\/wp\/v2\/pages\/1111"}],"collection":[{"href":"http:\/\/asiabiobank.com\/zh-hant\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/asiabiobank.com\/zh-hant\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/asiabiobank.com\/zh-hant\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/asiabiobank.com\/zh-hant\/wp-json\/wp\/v2\/comments?post=1111"}],"version-history":[{"count":6,"href":"http:\/\/asiabiobank.com\/zh-hant\/wp-json\/wp\/v2\/pages\/1111\/revisions"}],"predecessor-version":[{"id":1691,"href":"http:\/\/asiabiobank.com\/zh-hant\/wp-json\/wp\/v2\/pages\/1111\/revisions\/1691"}],"up":[{"embeddable":true,"href":"http:\/\/asiabiobank.com\/zh-hant\/wp-json\/wp\/v2\/pages\/1544"}],"wp:attachment":[{"href":"http:\/\/asiabiobank.com\/zh-hant\/wp-json\/wp\/v2\/media?parent=1111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}